RNASEL and cancer: Additionally, the ribonuclease targeting chimera (RIBOTAC) used RNA-targeting small molecules and RNase L to accomplish the degradation of intracellular RNAs [268, 269], suggesting a new idea for the degradation of oncogenic RNAs for cancer therapy.